AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Recce Pharmaceuticals (ASX:RCE) Strengthens Patent Portfolio with Chinese Approval, Boosting Presence in ASX200 Pharma Sector
May 26, 2025 12:57 PM AEST| By Team Kalkine MediaHighlights,Recce secures patent approval in China for key anti-infective drug candidates.,Patent covers multiple bacterial and viral infections with varied administration methods.,Expansion enhances Recce’s global intellectual property footprint in m...
Which Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?
May 23, 2025 06:18 PM AEST| By Team Kalkine MediaWhich Healthcare Leader in the S&P/ASX Two Hundred and ASX All Ordinaries Tops Global Fund Holdings?
ASX 200 Health Stocks Climb Amid Capital Raisings and Diagnostic Advancements
May 23, 2025 04:31 PM AEST| By Team Kalkine MediaHighlights:,Multiple ASX-listed healthcare firms initiate capital raisings to strengthen cash positions,EMVision showcases improved stroke diagnostic performance using AI at major health conference,Monash IVF updates FY25 outlook following operationa...
Mayne Pharma (ASX:MYX) Shares Show Partial Rebound Amid Takeover Uncertainty and ASX200 Volatility
May 23, 2025 02:41 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma shares recover after sharp weekly decline,FDA concerns impact takeover negotiations with US firm Cosette,Market watchers eye implications for ASX dividend stocks and ASX200,Mayne Pharma (ASX:MYX) shares experienced a partial r...
Hengrui’s Soaring Hong Kong Debut Sparks Optimism Across ASX200 and Global Pharma Markets
May 23, 2025 12:27 PM AEST| By Team Kalkine MediaHighlights,Hengrui jumps 29% in Hong Kong listing,$2 billion capital to fuel drug innovation,Market buzz adds momentum to ASX200,In a remarkable debut that has stirred enthusiasm among global investors,,Jiangsu Hengrui Pharmaceuticals (HKG:600276),,...
Nyrada’s Breakthrough TRPC Blocker Gains Momentum in ASX200 Medical Research Space
May 23, 2025 12:00 AM AEST| By Team Kalkine MediaHighlights,Drug shows promise for stroke, heart attack, and brain injury,Early trial data confirms safety and strong tissue preservation,Anti-arrhythmic effects observed in follow-up studies,Nyrada Inc. (ASX:NYR) has reported encouraging progress on...
Regeneron (NASDAQ:REGN) Moves to Acquire 23andMe Amid Market Shifts — What ASX200 Investors Should Know
May 23, 2025 12:00 AM AEST| By Team Kalkine MediaHighlights,Regeneron to acquire 23andMe’s core assets for $256 million,Customer DNA data security prioritized in the deal,Acquisition aligns with growing biotech innovation in ASX200 and beyond,Biotechnology leader Regeneron Pharmaceuticals (NASDAQ:R...
Could Mayne Pharma’s Deal Review Rattle ASX 200 and Health Care Index?
May 22, 2025 03:30 PM AEST| By Team Kalkine MediaCould Mayne Pharma’s Deal Review Rattle ASX 200 and Health Care Index?
Mayne Pharma Shares Hit New Low as ASX200 Pressure Mounts
May 22, 2025 01:42 PM AEST| By Team Kalkine MediaHighlights,Mayne Pharma faces steep decline amid investor uncertainty,FDA letter adds pressure as Cosette Pharmaceuticals reconsiders deal,Shares down over 39% since April peak,Mayne Pharma (ASX:MYX) continues to face headwinds as its shares hit fres...
Could AFT Pharmaceuticals Boost ASX and S&P Health Care Index Momentum?
May 22, 2025 10:30 AM AEST| By Team Kalkine MediaCould AFT Pharmaceuticals Boost ASX and S&P Health Care Index Momentum?
Pro Medicus (ASX:PME) Surges in ASX300: Exploring Healthcare Tech’s Strong Momentum
May 21, 2025 01:49 PM AEST| By Team Kalkine MediaHighlights,Pro Medicus sees double-digit growth in early 2025,Healthcare tech shines amid global sector momentum,PME valuation reflects rising demand for radiology software,Pro Medicus Ltd (ASX:PME), a leading name in medical imaging software, has co...
ASX 200 Financial Sector Watch: CBA, MYX, ADT in Spotlight Amid Index Fluctuations
May 21, 2025 01:30 PM AEST| By Team Kalkine MediaHighlights:,Commonwealth Bank (ASX:CBA) reaches a historic intraday high despite market uncertainties,Mayne Pharma (ASX:MYX) experiences steep decline following takeover withdrawal,Adriatic Metals (ASX:ADT) records share surge amid acquisition intere...
ASX200 Update: Nanosonics (ASX:NAN) Shares Climb Amid Market Query
May 21, 2025 12:47 PM AEST| By Team Kalkine MediaHighlights,Nanosonics,shares rise after addressing ASX query,Company unaware of reasons behind unusual trading activity,Previous,share movement linked to FDA approval in March,Shares of medical device firm Nanosonics (ASX:NAN) saw a notable rebound a...
ASX200 M&A Drama: Why Cosette Abandoned Its $672M Mayne Pharma Deal
May 21, 2025 12:40 PM AEST| By Team Kalkine MediaHighlights,Private equity bidder Cosette exits deal citing earnings and regulatory issues,Mayne Pharma's (MYX) stock tumbles 30% amid legal tussle,Market volatility, earnings downgrade, and FDA scrutiny shake confidence,In a dramatic turn of events t...
Debt Monitoring in Focus: Monash IVF Group (ASX:MVF) Navigates Liabilities on the ASX 200
May 21, 2025 12:33 PM AEST| By Team Kalkine MediaHighlights,Monash IVF Group (ASX:MVF) shows disciplined debt handling with increasing earnings,Free cash flow trends underline the company's financial management strategy,Rising net debt warrants close attention within broader balance sheet metrics,M...
ASX200 Biotech Watch: Mayne Pharma (ASX:MYX) Shares Sink as Cosette Flags Deal Risk
May 21, 2025 11:51 AM AEST| By Team Kalkine MediaHighlights,Mayne Pharma shares dropped,nearly 30%,amid acquisition uncertainty,Cosette Pharmaceuticals raises concerns over financial and legal issues,Potential impact on ASX200 biotech sector and investor sentiment,Mayne Pharma Group (ASX:MYX) saw i...
Cosette Flags Concerns Over Mayne Pharma Takeover Amid ASX200 Market Movements
May 21, 2025 10:55 AM AEST| By Team Kalkine MediaHighlights,Cosette questions Mayne Pharma’s financial stability,FDA letter raises issues over contraceptive product marketing,Mayne Pharma defends transparency and rejects change claims,In a development stirring interest among investors tracking the,...
Breakthrough Osteoarthritis Therapy by Paradigm Biopharmaceuticals (ASX:PAR) Sets New Benchmark on ASX 200
May 21, 2025 09:30 AM AEST| By Team Kalkine MediaHighlights:,Paradigm Biopharmaceuticals (ASX:PAR) is developing Zilosul, a PPS-based drug, to address osteoarthritis,Clinical trials show extended symptom relief and improved joint function,Exclusive partnership with bene pharmaChem strengthens manuf...
Is Sonic Healthcare (ASX:SHL) Undervalued in 2025? ASX 200 Healthcare Stock Review
May 20, 2025 06:01 PM AEST| By Team Kalkine MediaHighlights,Sonic Healthcare Ltd (ASX:SHL) operates across diagnostics and pathology sectors globally,The company’s key financial indicators show mixed performance trends in recent years,Shares are currently trading below their long-term average valua...
Visionflex Expands Telehealth Reach Through BHP Deal, Strengthening ASX300 Presence
May 20, 2025 01:36 PM AEST| By Team Kalkine MediaHighlights,Visionflex secures major telehealth rollout across BHP’s remote WA sites,Project targets improved healthcare access and reduced medevac needs,Visionflex also expands aged care support through virtual nursing initiative,Visionflex Group (AS...
Advertise your brand on Kalkine Media